| Literature DB >> 30652849 |
Tomoya Yukawa1, Yoshi Nara1, Mitsunori Kono1, Ayumu Sato1, Tsuneo Oda1, Terufumi Takagi1, Takayuki Sato1, Yoshihiro Banno1, Naohiro Taya1, Takashi Imada1, Zenyu Shiokawa1, Nobuyuki Negoro1, Tetsuji Kawamoto1, Ryokichi Koyama1, Noriko Uchiyama1, Robert Skene2, Isaac Hoffman2, Chien-Hung Chen2, BiChing Sang2, Gyorgy Snell2, Ryosuke Katsuyama1, Satoshi Yamamoto1, Junya Shirai1.
Abstract
Retinoic acid receptor-related orphan receptor γt (RORγt) agonists are expected to provide a novel class of immune-activating anticancer drugs via activation of Th17 cells and Tc17 cells. Herein, we describe a novel structure-based functionality switching approach from in house well-optimized RORγt inverse agonists to potent RORγt agonists. We succeeded in the identification of potent RORγt agonist 5 without major chemical structure change. The biochemical response was validated by molecular dynamics simulation studies that showed a helix 12 stabilization effect of RORγt agonists. These results indicate that targeting helix 12 is an attractive and novel medicinal chemistry strategy for switching existing RORγt inverse agonists to agonists.Entities:
Year: 2019 PMID: 30652849 DOI: 10.1021/acs.jmedchem.8b01181
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446